Speaker illustration

Doctor Henry Ginsberg

Columbia University, New York (United States of America)

Henry Ginsberg is the Irving Professor of Medicine and Past Director of the Irving Institute for Clinical and Translational Research at Columbia University. His research interests have centered on regulation of the metabolism of apolipoprotein B containing lipoproteins, including very low density lipoproteins, low density lipoproteins, and lipoprotein (a), in cells, mice and humans. He has published close to 400 peer-reviewed and invited papers. Dr. Ginsberg was the lead investigator of the ACCORD Lipid Trial. He has co-chaired an EAS Consensus Panel that has published major papers in the EHJ during the past decade. He has received funding from the NIH for more than 40 years and has collected numerous awards from the AHA, the ADA and the EAS. In 2017, Dr. Ginsberg received an NIH Outstanding Investigator Award with $4M of direct funding for 7 years. In addition to his research, Dr. Ginsberg has led NIH training grants for 30 years, and cares for patient with severe lipid disorders.

Are triglycerides the new LDL?

Event: ESC Preventive Cardiology 2022

Topic: European Association of Preventive Cardiology (EAPC)

Session: Dyslipidaemia management: a moving target!

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb